A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development
Tekijät: Verneri Virtanen, Kreetta Paunu, Johanna K. Ahlskog, Reka Varnai, Csilla Sipeky, Maria Sundvall
Kustantaja: MDPI
Julkaisuvuosi: 2019
Journal: Genes
Tietokannassa oleva lehden nimi: GENES
Lehden akronyymi: GENES-BASEL
Artikkelin numero: ARTN 565
Vuosikerta: 10
Numero: 8
Sivujen määrä: 19
eISSN: 2073-4425
DOI: https://doi.org/10.3390/genes10080565
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/42602759
Prostate cancer is globally the second most commonly diagnosed cancer type in men. Recent studies suggest that mutations in DNA repair genes are associated with aggressive forms of prostate cancer and castration resistance. Prostate cancer with DNA repair defects may be vulnerable to therapeutic targeting by Poly(ADP-ribose) polymerase (PARP) inhibitors. PARP enzymes modify target proteins with ADP-ribose in a process called PARylation and are in particular involved in single strand break repair. The rationale behind the clinical trials that led to the current use of PARP inhibitors to treat cancer was to target the dependence of BRCA-mutant cancer cells on the PARP-associated repair pathway due to deficiency in homologous recombination. However, recent studies have proposed therapeutic potential for PARP inhibitors in tumors with a variety of vulnerabilities generating dependence on PARP beyond the synthetic lethal targeting of BRCA1/BRCA2 mutated tumors, suggesting a wider potential than initially thought. Importantly, PARP-associated DNA repair pathways are also closely connected to androgen receptor (AR) signaling, which is a key regulator of tumor growth and a central therapeutic target in prostate cancer. In this review, we provide an extensive overview of published and ongoing trials exploring PARP inhibitors in treatment of prostate cancer and discuss the underlying biology. Several clinical trials are currently studying PARP inhibitor mono-and combination therapies in the treatment of prostate cancer. Integration of drugs targeting DNA repair pathways in prostate cancer treatment modalities allows developing of more personalized care taking also into account the genetic makeup of individual tumors.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
